Morgan Stanley Confirms Stable Trends On Hologic (HOLX)

Morgan Stanley provided color on Hologic HOLX in a research report published today. In the report, Morgan Stanley states, "Admittedly, many aspects of the business are beginning to stabilize, but visibility still remains clouded on the outlook for acquisition driven pipeline products, DTC surgical pull through and most importantly Tomosynthesis." Hologic increased its guidance revenue by $20 million and its earnings per share forecast for this year by $0.02. Morgan Stanley currently has an Equal-weight rating on Hologic's shares. In today's pre-trading session, Hologic's shares gained 2.59% to stand at $23.00.